AMPK in cardiac fibrosis and repair: Actions beyond metabolic regulation. (Q38698086)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26772531%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

AMPK in cardiac fibrosis and repair: Actions beyond metabolic regulation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26772531%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26772531%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Evangelos P Daskalopoulos

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26772531%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Luc Bertrand

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26772531%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Christophe Beauloye

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26772531%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Sandrine Horman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26772531%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

publication date

7 January 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26772531%20AND%20SRC:MED&resulttype=core&format=json

Journal of Molecular and Cellular Cardiology

5 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26772531%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

91

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26772531%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

188-200

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26772531%20AND%20SRC:MED&resulttype=core&format=json

AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure

5 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Metformin reduces airway inflammation and remodeling via activation of AMP-activated protein kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Activation of AMP-activated protein kinase inhibits ER stress and renal fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

AMP-activated protein kinase inhibits TGF-β-induced fibrogenic responses of hepatic stellate cells by targeting transcriptional coactivator p300.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Cellular and molecular mechanisms of fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Cardiac fibroblast: the renaissance cell

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Structural and functional characterisation of cardiac fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Myocardial extracellular matrix: an ever-changing and diverse entity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Patterns of myocardial fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Incremental prognostic value of myocardial fibrosis in patients with non-ischemic cardiomyopathy without congestive heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Cardiac (myo)fibroblast: Novel strategies for its targeting following myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Type II diabetes promotes a myofibroblast phenotype in cardiac fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Bone marrow-derived cells contribute to cell turnover in aging murine hearts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

M2 macrophage accumulation in the aortic wall during angiotensin II infusion in mice is associated with fibrosis, elastin loss, and elevated blood pressure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Caveolin-1 deletion exacerbates cardiac interstitial fibrosis by promoting M2 macrophage activation in mice after myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

RhoA signaling in cardiomyocytes protects against stress-induced heart failure but facilitates cardiac fibrosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Endothelial p53 deletion improves angiogenesis and prevents cardiac fibrosis and heart failure induced by pressure overload in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Bone marrow-derived cells contribute to fibrosis in the chronically failing heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

The pathogenesis of cardiac fibrosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

The extracellular matrix: at the center of it all.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

From inflammation to fibrosis: a stiff stretch of highway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Cross-linking influences the impact of quantitative changes in myocardial collagen on cardiac stiffness and remodelling in hypertension in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Osteoglycin prevents cardiac dilatation and dysfunction after myocardial infarction through infarct collagen strengthening.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Matrix metalloproteinase-9 deletion attenuates myocardial fibrosis and diastolic dysfunction in ageing mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Differential role of TIMP2 and TIMP3 in cardiac hypertrophy, fibrosis, and diastolic dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

AMPK: Lessons from transgenic and knockout animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Activation of AMPK alpha- and gamma-isoform complexes in the intact ischemic rat heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Embryonic expression of AMPK γ subunits and the identification of a novel γ2 transcript variant in adult heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

A small molecule AMPK activator protects the heart against ischemia-reperfusion injury.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKalpha2 but not AMPKalpha1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

The vestigial enzyme D-dopachrome tautomerase protects the heart against ischemic injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of Ser485/491.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Functional dissection of lysine deacetylases reveals that HDAC1 and p300 regulate AMPK

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

A redox-dependent mechanism for regulation of AMPK activation by Thioredoxin1 during energy starvation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

AMPK: a nutrient and energy sensor that maintains energy homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Structural basis of AMPK regulation by small molecule activators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Mechanism of action of compound-13: an α1-selective small molecule activator of AMPK

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Isoproterenol stimulates 5'-AMP-activated protein kinase and fatty acid oxidation in neonatal hearts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

AMP-activated protein kinase influences metabolic remodeling in H9c2 cells hypertrophied by arginine vasopressin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

AMP-activated protein kinase phosphorylates and desensitizes smooth muscle myosin light chain kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

C1q/Tumor Necrosis Factor-Related Protein 9 Protects against Acute Myocardial Injury through an Adiponectin Receptor I-AMPK-Dependent Mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Omentin prevents myocardial ischemic injury through AMP-activated protein kinase- and Akt-dependent mechanisms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Urocortin 2 autocrine/paracrine and pharmacologic effects to activate AMP-activated protein kinase in the heart.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Therapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

AMP-activated protein kinase in the control of cardiac metabolism and remodeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

AMPK mediates autophagy during myocardial ischemia in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Regulation of NAD(P)H oxidases by AMPK in cardiovascular systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

A-769662 potentiates the effect of other AMP-activated protein kinase activators on cardiac glucose uptake

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

AMPK-dependent inhibitory phosphorylation of ACC is not essential for maintaining myocardial fatty acid oxidation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

AMP-activated protein kinase deficiency enhances myocardial ischemia/reperfusion injury but has minimal effect on the antioxidant/antinitrative protection of adiponectin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Role of the alpha2-isoform of AMP-activated protein kinase in the metabolic response of the heart to no-flow ischemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Reduced scar maturation and contractility lead to exaggerated left ventricular dilation after myocardial infarction in mice lacking AMPKα1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Cardiac hypertrophy: the good, the bad, and the ugly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

AMPKalpha2 counteracts the development of cardiac hypertrophy induced by isoproterenol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Long-term activation of adenosine monophosphate-activated protein kinase attenuates pressure-overload-induced cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

3,3'-Diindolylmethane protects against cardiac hypertrophy via 5'-adenosine monophosphate-activated protein kinase-α2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

AMP-activated protein kinase α1 regulates cardiac gap junction protein connexin 43 and electrical remodeling following pressure overload.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Murine models of diastolic dysfunction and heart failure with preserved ejection fraction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha2 subunit of AMP-activated protein kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Pioglitazone ameliorates systolic and diastolic cardiac dysfunction in rat model of angiotensin II-induced hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Resveratrol treatment of mice with pressure-overload-induced heart failure improves diastolic function and cardiac energy metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Effects of pioglitazone on cardiac and adipose tissue pathology in rats with metabolic syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

AICAR-dependent AMPK activation improves scar formation in the aged heart in a murine model of reperfused myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Metformin is associated with improved left ventricular diastolic function measured by tissue Doppler imaging in patients with diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Is the failing heart energy starved? On using chemical energy to support cardiac function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Is AMPK the savior of the failing heart?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

AMPK, insulin resistance, and the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

α-Lipoic acid attenuates cardiac fibrosis in Otsuka Long-Evans Tokushima Fatty rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Dissociation of Bcl-2-Beclin1 complex by activated AMPK enhances cardiac autophagy and protects against cardiomyocyte apoptosis in diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Hypertension is a conditional factor for the development of cardiac hypertrophy in type 2 diabetic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Aging-associated cardiovascular changes and their relationship to heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Mitochondrial aldehyde dehydrogenase 2 accentuates aging-induced cardiac remodeling and contractile dysfunction: role of AMPK, Sirt1, and mitochondrial function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Reduced expression of MYC increases longevity and enhances healthspan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Transforming growth factor (TGF)-β signaling in cardiac remodeling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

AMP-activated protein kinase inhibits transforming growth factor-beta-induced Smad3-dependent transcription and myofibroblast transdifferentiation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

CTRP3 attenuates post-infarct cardiac fibrosis by targeting Smad3 activation and inhibiting myofibroblast differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Remodeling of the rat right and left ventricles in experimental hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Crosstalk between AMPK activation and angiotensin II-induced hypertrophy in cardiomyocytes: the role of mitochondria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPAR-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

The Wnt signaling pathway in development and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Targeting the Wnt/frizzled signaling pathway after myocardial infarction: a new tool in the therapeutic toolbox?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Loss of secreted frizzled-related protein-1 leads to deterioration of cardiac function in mice and plays a role in human cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Exogenously administered secreted frizzled related protein 2 (Sfrp2) reduces fibrosis and improves cardiac function in a rat model of myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Calcium/calmodulin-dependent protein kinase II couples Wnt signaling with histone deacetylase 4 and mediates dishevelled-induced cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

AMP-activated protein kinase (AMPK) cross-talks with canonical Wnt signaling via phosphorylation of beta-catenin at Ser 552.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

AMP-activated protein kinase attenuates Wnt/β-catenin signaling in human osteoblastic Saos-2 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Endothelial NADPH oxidase-2 promotes interstitial cardiac fibrosis and diastolic dysfunction through proinflammatory effects and endothelial-mesenchymal transition.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Myocardial fibrosis induced by exposure to subclinical lipopolysaccharide is associated with decreased miR-29c and enhanced NOX2 expression in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Nox4 modulates collagen production stimulated by transforming growth factor β1 in vivo and in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

α1AMP-activated protein kinase preserves endothelial function during chronic angiotensin II treatment by limiting Nox2 upregulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Effects of AT1- and beta-adrenergic receptor antagonists on TGF-beta1-induced fibrosis in transgenic mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Effects of direct Renin inhibition on myocardial fibrosis and cardiac fibroblast function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Eplerenone-mediated regression of electrical activation delays and myocardial fibrosis in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24 hours after administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Metformin inhibits angiotensin II-induced differentiation of cardiac fibroblasts into myofibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Evidence for the importance of adiponectin in the cardioprotective effects of pioglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

A DPP-4 inhibitor suppresses fibrosis and inflammation on experimental autoimmune myocarditis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Effects of DPP-4 inhibition on cardiac metabolism and function in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Activation of AMPK by berberine promotes adiponectin multimerization in 3T3-L1 adipocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Berberine attenuates adverse left ventricular remodeling and cardiac dysfunction after acute myocardial infarction in rats: role of autophagy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Knockout of beta(1)- and beta(2)-adrenoceptors attenuates pressure overload-induced cardiac hypertrophy and fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Effects of beta-adrenergic inhibition on scar formation after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Adrenergic regulation of AMP-activated protein kinase in brown adipose tissue in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

AMP-activated protein kinase activation by adrenoceptors in L6 skeletal muscle cells: mediation by alpha1-adrenoceptors causing glucose uptake

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Nebivolol exerts beneficial effects on endothelial function, early endothelial progenitor cells, myocardial neovascularization, and left ventricular dysfunction early after myocardial infarction beyond conventional β1-blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

HMG-CoA reductase inhibition prior reperfusion improves reparative fibrosis post-myocardial infarction in a preclinical experimental model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Statins activate AMP-activated protein kinase in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Pravastatin accelerates ischemia-induced angiogenesis through AMP-activated protein kinase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Cell-type specificity of inhibition of glycolysis by 5-amino-4-imidazolecarboxamide riboside. Lack of effect in rabbit cardiomyocytes and human erythrocytes, and inhibition in FTO-2B rat hepatoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Enhancing AMPK activation during ischemia protects the diabetic heart against reperfusion injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Enhanced activation of cellular AMPK by dual-small molecule treatment: AICAR and A769662.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Novel small-molecule AMPK activator orally exerts beneficial effects on diabetic db/db mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Adiponectin-mediated modulation of hypertrophic signals in the heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Adiponectin mediated APPL1-AMPK signaling induces cell migration, MMP activation, and collagen remodeling in cardiac fibroblasts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Adiponectin protects against doxorubicin-induced cardiomyopathy by anti-apoptotic effects through AMPK up-regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Deficiency in adiponectin exaggerates cigarette smoking exposure-induced cardiac contractile dysfunction: Role of autophagy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

AdipoRon, the first orally active adiponectin receptor activator, attenuates postischemic myocardial apoptosis through both AMPK-mediated and AMPK-independent signalings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Therapeutic potential of resveratrol in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Modulating effect of SIRT1 activation induced by resveratrol on Foxo1-associated apoptotic signalling in senescent heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Activation of SIRT3 by resveratrol ameliorates cardiac fibrosis and improves cardiac function via the TGF-β/Smad3 pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Resveratrol improves health and survival of mice on a high-calorie diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Protective effect of resveratrol against doxorubicin-induced cardiac toxicity and fibrosis in male experimental rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Protective effect of resveratrol against pressure overload-induced heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Resveratrol ameliorates cardiac dysfunction induced by pressure overload in rats via structural protection and modulation of Ca(2+) cycling proteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

C1q/tumor necrosis factor-related protein-6 attenuates post-infarct cardiac fibrosis by targeting RhoA/MRTF-A pathway and inhibiting myofibroblast differentiation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

C1q/tumor necrosis factor-related protein-9, a novel adipocyte-derived cytokine, attenuates adverse remodeling in the ischemic mouse heart via protein kinase A activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Indole-3-carbinol protects against pressure overload induced cardiac remodeling via activating AMPK-α.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Omentin functions to attenuate cardiac hypertrophic response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Intake of fermented beverages protect against acute myocardial injury: target organ cardiac effects and vasculoprotective effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

CHIP protects against cardiac pressure overload through regulation of AMPK.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Ablation of cereblon attenuates myocardial ischemia-reperfusion injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Treatment with brain natriuretic peptide prevents the development of cardiac dysfunction in obese diabetic db/db mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Protective effects of desacyl ghrelin on diabetic cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Sulforaphane prevents the development of cardiomyopathy in type 2 diabetic mice probably by reversing oxidative stress-induced inhibition of LKB1/AMPK pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Cardiac-specific leptin receptor deletion exacerbates ischaemic heart failure in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

A novel mechanism by which SDF-1β protects cardiac cells from palmitate-induced endoplasmic reticulum stress and apoptosis via CXCR7 and AMPK/p38 MAPK-mediated interleukin-6 generation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Macrophage migration inhibitory factor deletion exacerbates pressure overload-induced cardiac hypertrophy through mitigating autophagy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Direct AMP-activated protein kinase activators: a review of evidence from the patent literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

Regulation of interplay between autophagy and apoptosis in the diabetic heart: new role of AMPK.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.01.001

10.1016/J.YJMCC.2016.01.001

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26772531%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference